This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e100. Learning Objective-Upon completion of this activity, successful learners will be able to identify rate and risk factors associated with colonic low-grade dysplasia in patients with ulcerative colitis.
T he risk of colorectal cancer (CRC) is 2-5 times higher in patients with ulcerative colitis (UC) than the general population, and it is a major cause of morbidity and mortality among these individuals. [1] [2] [3] [4] In contrast to sporadic CRC, which arises from 1-2 foci of dysplastic changes and follows a well-recognized adenoma-carcinoma sequence, colitis-associated CRC results from a field change effect with multifocal genetic alterations that do not follow the typical adenomacarcinoma sequence of events. 5 Neoplasia development in long-standing UC progresses from nondysplastic mucosa, to visible or invisible low-grade dysplasia (LGD), high-grade dysplasia (HGD), to carcinoma. Periodic surveillance for colorectal neoplasia is recommended for patients with long-standing UC (or those with associated primary sclerosing cholangitis [PSC] ), and during surveillance, pooled prevalence of LGD is 9.4%. [6] [7] [8] Although management of nondysplastic UC (continued periodic surveillance) or UC-HGD (colectomy or endoscopic resection with intensive surveillance) is well accepted, management of UC-LGD is controversial. It is unclear whether these patients should continue surveillance or proceed to surgery, especially in case of nonvisible or nonendoscopically resectable dysplasia. [8] [9] [10] [11] This is, in part, caused by limited understanding of the natural history of UC-LGD, with regard to rate and risk factors for progression to HGD and/or CRC and presence of synchronous CRC. In a systematic review of 7 studies in patients with UC-LGD published over a decade ago, the estimated annual incidence of progression to CRC was 1.4% and to advanced neoplasia (CRC and/or HGD) was 3.0%. 6 However, there was no synthesis of risk factors associated with dysplasia progression (which may help risk stratify patients to avoid potential oversurveillance in a subset of low-risk patients, and undersurveillance in a subset of high-risk patients), and no assessment of dysplastic findings at colectomy specimens in patients with UC-LGD who opted to undergo surgery (and hence, no assessment of possibility of synchronous, potentially missed, CRC).
In this updated systematic review and meta-analysis, we estimated the incidence and risk factors for progression to CRC and/or HGD in patients who continued surveillance after UC-LGD diagnosis (surveillance cohorts); and prevalence and degree of dysplasia in the surgical specimen among patients who underwent colectomy for UC-LGD (surgical cohorts). With the increasing uptake of advanced dysplasia detection techniques, such as chromoendoscopy with higher rates of detecting LGD, these data would enable a more personalized approach to management of UC-LGD and aid shared-decision making for these patients.
Methods
We followed an a priori protocol registered at the International Prospective Register of Systematic Reviews (PROSPERO CRD42016033500), and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. 12 
Study Selection
To address the 2 primary aims of this review, 2 sets of inclusion criteria were used. To estimate rate and risk factors associated with progression of LGD, we included cohort studies in (1) adults with UC-LGD identified during colonoscopy (visible or nonvisible, resectable or nonresectable), (2) who continued periodic colonoscopic surveillance (had at least 1 follow-up colonoscopy after the initial LGD diagnosis), and (3) specified number of patients with UC-LGD who developed CRC and/or HGD, along with the total person-years or mean/median follow-up for the subset of patients with UC-LGD. These studies formed the surveillance cohort. We excluded (1) case-control studies, cross-sectional studies, and case series; (2) studies that did not specify the number of patients with UC-LGD who developed CRC and/or HGD; (3) studies that did not report follow-up duration; and (4) studies that selectively reported only outcome after adenoma-like or polypoid lesion.
To assess dysplasia-related findings on colectomy in patients with UC-LGD, we included cohort studies or case series (>1 patient) in (1) adults with UC-LGD identified during colonoscopy (visible or nonvisible, resectable or nonresectable); (2) who underwent colectomy at time of first diagnosis of UC-LGD (without any subsequent colonoscopy); and (3) specified number of patients who were diagnosed with no dysplasia, LGD, HGD, and CRC in the surgical specimen (worst finding), with at least 75% follow-up (ie, dysplasia-related findings reported for at least 75% of patients who underwent surgery for UC-LGD). These studies formed the surgical cohort. Studies in which dysplasia-related findings were reported for <75% of cohort, and where findings for HGD and CRC were not separately reported (ie, where HGD and CRC were grouped as advanced neoplasia) were excluded. In case of multiple publications from the same cohort, data from the most recent comprehensive report were included.
Search Strategy
A systematic literature search of multiple electronic databases was conducted from inception to November 30, 2015 , in adults with no language restrictions; this search was updated on June 1, 2016. The databases included Ovid Medline, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, Web of Science, and Scopus. The search strategy was designed and conducted by an experienced medical librarian with input from the study's investigators, using controlled vocabulary supplemented with keywords, for studies on dysplasia in UC. The details of the search strategy are reported in the Supplementary Appendix.
In addition, conference abstracts (Digestive Disease Week, United European Gastroenterology Week, American College of Gastroenterology annual meeting, Advances in Inflammatory Bowel Diseases meeting organized by the Crohn's and Colitis Foundation of America, and European Crohn's and Colitis Organization annual meeting) from 2012 to 2015, and bibliography of the selected articles and review articles on the topic were manually searched for additional studies, with no language restrictions. Two reviewers (MF and PSD) independently assessed the title and abstract of studies identified in the primary search for inclusion, and the full text of remaining articles were examined to determine whether they met inclusion criteria. Any discrepancy in article selection was resolved by consensus, and in discussion with a third reviewer (SS). A reviewer (MF) contacted the primary study authors as needed for additional data or missing information.
Data Abstraction and Definition
Two authors (MF and PSD) independently abstracted data on (1) study characteristics of primary author, time period of study/year of publication, country of origin, and study setting (population-based or referral center); (2) UC-related characteristics of total number patients with UC (if unavailable, total number of patients with inflammatory disease [IBD] ) and UC-LGD, duration of follow-up (total person-years of follow-up after diagnosis of UC-LGD), and number of biopsy specimens taken during surveillance; (3) demographic characteristics of age at UC diagnosis/LGD diagnosis, disease duration, sex, familial history of colorectal neoplasia, extent of UC, concomitant PSC, smoking status, and use of UC-related medications; (4) dysplasia-related characteristics of visible versus nonvisible dysplasia, unifocal versus multifocal, size and location (distal vs proximal) of dysplastic lesion, associated stricture, and pathologic confirmation of LGD (single or consensus of pathologists, expert vs community); and (5) outcomes of number of patients with UC-LGD who developed HGD and/or CRC (and associated clinical and dysplasia-related characteristics).
For the surgical cohort, dysplasia-related findings on pathologic specimens were abstracted. For analysis, "indefinite for dysplasia" was considered equivalent to no dysplasia. Nonvisible dysplasia was defined by an absence of documented endoscopic abnormalities. Visible dysplasia was defined as dysplasia-associated lesion or mass, adenoma-like mass, or raised or endoscopically visible flat dysplasia.
Quality Assessment
The quality of included studies was assessed using a scale derived from the Newcastle-Ottawa scale for cohort studies, and has been used in a similar study on risk of progression of Barrett's esophagus with LGD. 13 This quality score consisted of 7 questions: representative of the average adult in the community, large cohort size, definite histologic confirmation of LGD, adequate followup of cohort for outcome to occur, clear information on duration of follow-up of patients with UC-LGD, attrition rate, definite information on progression of UC-LGD (Supplementary Appendix). A score of 6, 4-5, and 3 was considered suggestive of high-, medium-, and low-quality study.
Outcomes Assessed
For the surveillance cohort, the primary outcome was the incidence rate (IR) of CRC, and the secondary outcome was incidence of composite outcome of advanced neoplasia (CRC and/or HGD). A priori hypotheses to explain potential heterogeneity in the incidence of CRC among different observational studies included location of study (North America vs Europe), and whether diagnosis of LGD was confirmed by single versus consensus of pathologists. Sensitivity analyses were performed to assess stability of findings after excluding low-quality studies, and studies in which >50% patients had concomitant PSC was also performed.
To identify risk factors associated with progression of UC-LGD to advanced neoplasia, we systematically reviewed UC-related (age at UC diagnosis, sex, disease duration, presence of concomitant PSC) and dysplasiarelated factors (age at LGD diagnosis, invisible vs visible dysplasia, unifocal vs multifocal dysplasia, onetime vs persistent LGD, location of dysplasia) associated with progression of UC-LGD to advanced neoplasia. We also qualitatively reviewed the prognosis of CRC diagnosed during surveillance of patients with UC-LGD.
For the surgical cohort, the primary outcome of interest was the proportion of patients with no dysplasia (or indefinite for dysplasia), LGD, HGD, and CRC in the surgical specimen after colectomy for UC-LGD.
Statistical Analysis
The summary measure for the surveillance cohort was pooled IR (and 95% confidence interval [CI]), and was estimated using the random effects model proposed by DerSimonian and Laird.
14 To identify risk factors associated with progression of dysplasia, we pooled maximally adjusted odds ratio (OR; to account for confounding variables), where reported, using random-effects model. For the surgical cohort, the summary measure was the pooled and weighted prevalence of different dysplasiarelated findings. We assessed heterogeneity using the I 2 statistic. Values of <30%, 30%-59%, 60%-75%, and >75% were classified as low, moderate, substantial, and considerable heterogeneity, respectively. 15 Betweenstudy sources of heterogeneity were assessed using subgroup analyses defined previously. A P value for differences between subgroups of < .10 was considered statistically significant. Publication bias was assessed quantitatively using Egger regression test (publication bias considered present if P .10), and qualitatively, by visual inspection of funnel plots. 16, 17 All analyses were performed using Comprehensive Meta-Analysis software, version 2 (Biostat, Englewood, NJ).
Results
Of 3609 unique studies identified using our search strategy, 14 surveillance cohorts and 12 surgical cohorts were included. Forty-four studies were excluded, primarily because of insufficient data to calculate IR of progression of dysplasia in patients with UC-LGD (Figure 1 ).
Surveillance Cohorts
Characteristics and Quality of Included Studies. Fourteen studies reporting on 671 individuals with UC-LGD with total 4238 patient years of follow-up formed the surveillance cohort. 7, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] The characteristics of these studies are summarized in Table 1 . Seven studies were performed in Europe, and 7 in North America. All studies, except 1, were single, referral-center studies. An expert pathologist in 11 cohorts confirmed LGD, and for 3 studies, a community pathologist alone diagnosed LGD. Associated factors with progression from LGD to advanced neoplasia were available in 6 studies. 7, [18] [19] [20] 23, 25 The quality of the included studies is shown in Supplementary Table 1 . There was no high-quality study; 4 studies were classified as low-quality.
Incidence of Colorectal Cancer and Advanced
Neoplasia. On meta-analysis of 14 studies in 671 patients with UC-LGD under surveillance, 52 patients developed CRC. The pooled IR of CRC was 0.8 per 100 patient-year follow-up (95% CI, 0.4-1.3), with substantial heterogeneity across studies (I 2 ¼ 65%) (Figure 2 ). Similarly, the pooled incidence of advanced neoplasia was 1.8 per 100 patient-year (95% CI, 0.9-2.7), with considerable heterogeneity (I 2 ¼ 82%) (Figure 3 ). Five studies reported rates of progression to advanced neoplasia in patients with nonvisible (flat) LGD and endoscopically Table 1 . visible dysplasia (dysplasia-associated lesion or mass/ adenoma-like lesion), separately. [19] [20] [21] 23, 24 On metaanalysis, pooled IR of advanced neoplasia in patients with nonvisible LGD was 6.1 per 100 patient-year followup (95% CI, 0.9-11.4), and with endoscopically visible dysplasia was 1.0 per 100 patient-year follow-up (95% CI, 0-2.1).
In exploring potential sources of heterogeneity, the risk of progression to CRC was significantly lower in studies in which LGD was diagnosed by community pathologists without expert confirmation (IR, 0.2 per 100 patient-years; 95% CI, 0.0-0.4; 3 studies); the corresponding incidence in studies with confirmation by expert pathologists was 1.5% (95% CI, 0.6-2.4; 10 studies; P interaction ¼ .006). There were no significant differences in IR of CRC between studies conducted in Europe (IR, 0.7; 95% CI, 0.1-1.4; 7 studies) versus North America (IR, 1.0; 95% CI, 0.3-1.7; 7 studies; P interaction ¼ .54). Only 1 study reported a potential beneficial effect between receipt of chromoendoscopy and lower risk of progression to advanced neoplasia in patients with LGD (hazard ratio, 0.5; 95% CI, 0.3-1.0). 7 On sensitivity analysis, the incidence of CRC was similar to the primary estimate after excluding low-quality studies (IR, 1.0; 95% CI, 0.3-1.6; 10 studies) and after excluding studies with high proportion of patients with concomitant PSC (IR, 0.8; 95% CI, 0.3-1.3; 12 studies). After excluding 2 studies with very high observed rate of progression, including 1 study performed exclusively in patients with flat LGD, 7,23 a more conservative IR of progression to CRC was 0.4 per 100 patient-years (95% CI, 0.1-0.8) and advanced neoplasia was 1.2 per 100 patient-years (95% CI, 0.5-1.9). Because of considerable heterogeneity, assessment of publication bias was unreliable.
Risk Factors Associated with Progression to Advanced
Neoplasia. Six studies reported various UC-and dysplasia-related factors associated with progression of UC-LGD to advanced neoplasia. 7, [18] [19] [20] 23, 25 Where 2 studies reported on same risk factor, meta-analysis was performed and is summarized in Table 2 . Concomitant PSC (OR, 3.4; 95% CI, 1.5-7.8), invisible dysplasia (vs visible dysplasia; OR, 1.9; 95% CI, 1.0-3.4), distal dysplasia location (vs proximal to splenic flexure; OR, 2.0; 95% CI, 1.1-3.7), and multifocal dysplasia (vs unifocal dysplasia; OR, 3.5; 95% CI, 1.5-8.5) were significantly associated with progression to advanced neoplasia. There was no significant association between age at diagnosis of UC or LGD, sex, and disease duration. Persistent or metachronous LGD (vs incident LGD) was also not independently associated with increased risk of progression to advanced neoplasia (OR, 1.4; 95% CI, 0.6-3.3). In 1 study, dysplastic lesion >1 cm (hazard ratio, 3.8; 95% CI, 1.5-13.4) and previous history of "indefinite for dysplasia" (hazard ratio, 2.8; 95% CI, 1.2-6.5) was associated with increased risk of progression to advanced neoplasia. 7 
Surgical Cohorts
Advanced Neoplasia in Patients Undergoing Colectomy for Ulcerative Colitis With Low-Grade Dysplasia. We identified 12 surgical cohort studies of 450 patients who underwent colectomy for LGD (Table 3) . 7, 21, 22, 28, [31] [32] [33] [34] [35] [36] [37] Overall, findings at time of surgery were no dysplasia, 37% (95% CI, 29-47; 197 
Outcome after Colorectal Cancer Diagnosis
Eight studies reported outcome after diagnosis of 12 CRC.
21-23,27-31 Among these, 11 patients underwent surgery with curative intent. Overall, 2 patients died during follow-up, both related to CRC: 1 patient died because of metastatic CRC, and another following recurrence of CRC after initial curative surgery.
Discussion
The management of UC-LGD is challenging because of a limited understanding of its natural history with regard to rate of metachronous or synchronous CRC, and risk factors associated with progression of dysplasia. In this systematic review of 14 surveillance cohorts and 12 surgical cohorts, we made several important observations. First, among patients with UC-LGD undergoing surveillance, the annual incidence of CRC is approximately 0.8% (95% CI, 0.4-1.3); rates of progression to CRC were higher when LGD was diagnosed by at least 1 expert gastrointestinal pathologist (IR, 1.5%; 95% CI, 0.6-2.4) as compared with a community pathologist without expert confirmation (IR, 0.2%; 95% CI, 0.0-0.4). Second, dysplastic lesions that were multifocal, invisible, located in the distal colon, or those detected in patients with concomitant PSC had the higher risk of progression to advanced neoplasia, and variable distribution of these risk factors in included surveillance cohorts may also explain observed heterogeneity. In particular, in patients with invisible dysplasia, annual incidence of progression to advanced neoplasia was 6.1% (95% CI, 0.9-11.4), and with endoscopically visible dysplasia was 1.0% (95% CI, 0-2.1).
Finally, we observed that among patients with UC-LGD undergoing colectomy, advanced neoplasia is observed in approximately 30% of patients, whereas in 70% patients, either no dysplasia, "indefinite for dysplasia," or LGD is identified; the risk of identifying synchronous CRC was significantly higher in older studies (published in 1990s, 33%) as compared with more contemporary cohorts (published in 2000s, 11%). Together, these findings comprehensively inform clinical practice on the natural history of UC-LGD and will facilitate shared decision-making regarding intensive endoscopic surveillance versus early colectomy in patients with UC-LGD. The observed annual incidence of CRC (0.8%; 95% CI, 0.4-1.3) and advanced neoplasia (1.8%; 95% CI, 0.9-2.7) was lower than observed in the previous systematic review (1.4% and 3.0%, respectively); the previous review included only 7 studies, primarily conducted in the 1990s before widespread uptake of surveillance for CRC, and predated advanced dysplasia detection techniques. 6 We identified 8 additional studies since the publication of the last review, and observed lower rates of progression to CRC and advanced neoplasia in our meta-analysis. This might be a true finding with an actual decrease in rate of dysplasia progression with widespread use of disease-modifying therapy that control inflammation better and hence, decrease risk of dysplasia progression, lead-time bias with higher rates of LGD detection at low-risk of progression with surveillance examinations, and advanced dysplasia detection techniques, or may be attributed to publication bias (with unreported studies) in the earlier meta-analysis. In contrast to UC-LGD, estimated annual incidence of CRC in unselected patients with nondysplastic UC is 0.3%, 38 and between 0.017% and 0.041% in the general CRC screening population. 39, 40 We observed wide variability in rates of progression to CRC across studies. This could be explained by 2 potential reasons. First, the studies were conducted in diverse clinical practices with wide variability in interpretation of LGD diagnosis. In studies where LGD was diagnosed only by a community pathologist, rates of progression to CRC were lower, as compared with studies with expert pathologic confirmation. Analogous to LGD in patients with Barrett's esophagus, UC-LGD may be overcalled by community pathologists, such that these patients are intrinsically at lower risk of progression to CRC. 13, 41, 42 In a Dutch pathology registry study, on re-review of 70 patients initially diagnosed as having flat LGD by 3 expert pathologists, the diagnosis of flat LGD was confirmed in only 21 patients (30%); in 29 patients (41%), the diagnosis was downgraded to indefinite for dysplasia, in 17 patients (24%) to no dysplasia, and in 3 patients (5%) to non-IBD-related dysplasia. 23 Although the rate of progression to advanced neoplasia in patients originally classified as having flat LGD was 19%, this rate increased to 44% on restricting to patients confirmed as having LGD by 3 expert pathologists. Second, there may be referral bias wherein expert centers may be more likely providing care to patients at highest risk of dysplasia progression.
An apparent discrepancy was observed in rates of metachronous CRC (from surveillance cohorts; annual IR, 0.8%) and synchronous CRC (from surgical cohorts; 17%). We hypothesize that these differences may be caused by (1) differences in patient population (systematic difference in patients with LGD who undergo surveillance, and those who undergo surgery, where (48) 74 (34) 36 (16) 5 (2) 41 ( (51) 46 (34) 16 (12) 4 (3) 20 ( (25) 13 (36) 5 (14) 9 (25) 14 ( (12) 2 (24) 3 (37) CD, Crohn's disease. physicians may be intuitively referring patients deemed to be at high risk of progression to surgery, and selectively including low-risk LGD patients in surveillance), (2) differences in time period (most surgical cohorts were published before 2000 and most surveillance cohorts were published after 2000, and with regular use of surveillance colonoscopies and advanced dysplasia detection techniques in recent times may enable early identification of LGD at low risk of harboring synchronous advanced neoplasia), or by (3) potential missed or interval CRCs. In surveillance cohorts, we assumed that risk of CRC increases linearly with time. It is possible that most patients who are diagnosed with CRC after a diagnosis of LGD develop CRC within 1-2 years of LGD diagnosis, and that these cancers were probably missed at the original colonoscopy, rather than truly being incident cancers, akin to observations in patients with Barrett's esophagus, in which we estimated that about 25% of esophageal cancers in patients with Barrett's esophagus develop within 2 years of initial Barrett's esophagus diagnosis. 43 In a study from the Netherlands on magnitude of interval CRCs in patients with IBD, the investigators observed that whereas the annual incidence of LGD in patients with IBD is 5.2%, about 1.3% patients developed interval CRC, possibly caused by inadequate colonoscopy, inadequate surveillance intervals, inadequate dysplasia management, or true biologic interval CRC. 44 The strengths of this systematic review include (1) comprehensive and systematic literature search with well-defined inclusion criteria; (2) quantitatively and qualitatively studying all aspects of dysplasia progression in patients with UC-LGD including incidence, risk factors and outcomes of metachronous CRC and advanced neoplasia, and risk of synchronous CRC and advanced neoplasia; (3) subgroup and sensitivity analyses to evaluate the stability of findings and identify potential factors responsible for inconsistencies; and (4) rigorous quality assessment of studies.
Our study has several limitations. First, significant heterogeneity was observed in the pooled estimate of incidence of dysplasia progression. We explored and identified potential explicit study-related (study setting, location, time period, whether diagnosis was confirmed by expert gastrointestinal pathologist) and implicit patient-related factors (UC-and dysplasia-related potential risk factors) that may be contributing to this heterogeneity. Second, studies did not consistently report the frequency of endoscopic surveillance, use of advanced dysplasia detection techniques as chromoendoscopy, and numbers of random and/or targeted biopsies taken in the surveillance cohorts. 45 Similarly, for surgical cohorts, there was incomplete reporting in terms of all dysplastic findings, resulting in exclusion of some studies with incomplete information. In assessing risk factors, several studies only provided univariate analysis because of limited number of events. Some potentially important risk factors, such as disease extent, associated stricture, familial history of CRC, or impact of IBD therapies and associated endoscopic and/or histologic remission on dysplasia progression, could not be evaluated because of insufficient data. Third, there was variability in study quality especially with regard to duration of follow-up, attrition rate, and specific reporting of follow-up in a subset of patients with UC-LGD. Moreover, most of the included studies were performed in referral centers, and these tend to overestimate CRC risk as compared with population-based studies. 46 In fact, we did not identify any high-quality study on this topic because of the aforementioned factors in this review. Finally, the analyses were done assuming that IR is constant over time, which may not be accurate.
Implications for Clinical Practice
Recently, the SCENIC consensus statements have proposed an individualized approach to surveillance in patients with UC-LGD. 8 Based on our observations, we recommend early repeat colonoscopy (within 6m), preferably with chromoendoscopy, in patients diagnosed with LGD, particularly invisible dysplasia, because of potential missed CRCs in these patients. Given low rates of progression to advanced neoplasia in patients with endoscopically visible lesions, we agree with the SCENIC consensus statements, that in patients with visible nonpolypoid dysplastic lesions that are amenable to endoscopic resection, surveillance colonoscopy may be suggested rather than colectomy. Finally, in patients with invisible dysplasia, we propose risk-stratification to identify patients at low and high risk of dysplasia progression, based on presence of absence of risk factors associated with dysplasia progression (concomitant PSC, multifocal LGD, previous indefinite for dysplasia, and distal location). Choi et al 7 estimated risk of dysplasia progression based on number of risk factors, and observed a significant increase in risk if multiple risk factors were present. Hence, in patients with multiple high-risk features, particularly those who may be difficult to survey (multiple pseudopolyps, poor compliance, ongoing active disease, and so forth), early colectomy may be advisable. However, there are significant differences in patients' and physicians' willingness to undergo colectomy for dysplasia risk, and hence, shared decisionmaking is recommended. 47 In conclusion, we estimate that the annual rate of progression to CRC or to advanced neoplasia in patients with UC-LGD under surveillance is approximately 0.8% (95% CI, 0.4-1.3) and 1.8% (95% CI, 0.9-2.7), respectively, and this rate may be variable depending on whether or not diagnosis of LGD was confirmed by an expert gastrointestinal pathologist. Concomitant PSC, invisible dysplasia, distal colonic location, and multifocal LGD are potential high-risk features associated with progression to advanced neoplasia. Among patients undergoing colectomy for UC-LGD, about 17% may have synchronous CRC, and this rate seems to have decreased over time potentially because of regular surveillance and advanced dysplasia detection techniques that enable early LGD diagnosis. Prospective, population-based observational cohort studies in patients with an expert pathologist-confirmed LGD are warranted to better understand the natural history of UC-LGD.
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